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A CASE REPORT
Wu-Pin Tseng, Jui-Hsiu Tsai,1 Ming-Tsang Wu, Chia-Tsuan Huang, and Hong-Wen Liu
Department of Family Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital,
and 1Department of Psychiatry, Kaohsiung Municipal Hsiao-Kang Hospital,
Kaohsiung Medical University, Kaohsiung, Taiwan.
Serotonin syndrome is a disorder resulting from excess stimulation of serotonin and is associated with
drug interaction, single-drug therapy, and overdose. We report a case involving a 32-year-old man who
developed sudden agitation, diaphoresis, subjective fever, tremor, and insomnia. These symptoms were
related to doubling the dose of citalopram in combination antidepressant therapy. Discontinuation of
the agent resulted in early notable clinical resolution after 1 week. This is a rare report of serotonin syndrome
induced by citalopram polytherapy. Although serotonin syndrome is rare, clinicians need to recognize
it early.
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Serotonin syndrome is a disorder resulting from excess
stimulation of serotonin (5-hydroxytryptamine, 5-HT),
especially 5-HT1A and 5-HT2 receptors, in the brainstem
and spinal cord [1,2]. The onset of serotonin syndrome is
observed within 24 hours following administration or
overdose of the serotonergic agent [2]. It is characterized
clinically by the sudden onset of a triad of symptoms
consisting of cognitive or behavioral changes (agitation,
hypomania, confusion), autonomic instability (hyper-
thermia, diaphoresis, diarrhea, mydriasis, tachycardia), and
neurologic changes (hyperreflexia, myoclonus, tremor,
incoordination, rigidity). Other causes such as infection,
substance abuse, or withdrawal must be excluded before
making a diagnosis of serotonin syndrome [2,3]. Because
serotonin syndrome is rare [4,5], most general practitioners
are unaware of the condition [6]. We report a case of
serotonin syndrome that was related to doubling of the
dose of citalopram in combination drug therapy, and that
subsided after discontinuation of the offending drug. The
syndrome has rarely been reported in association with
citalopram, an antidepressant [2]. We emphasize the need
for increased awareness of this syndrome when using this
agent.
CASE PRESENTATION
A 32-year-old man had been diagnosed with major
depressive disorder associated with a stressful internship
5 months before he presented to our clinic. He had been
taking citalopram (20 mg/day), flupentixol (0.5 mg/day),
and melitracen (10 mg/day) for more than 3 months. He
had recently self-initiated an increase in his dose of
citalopram to 40 mg/day due to worsening depressive
mood. Two days later, he suffered from agitation and
insomnia. In our clinic, he was alert and complained of
insomnia, diaphoresis, subjective fever, tremor, agita-
tion, constipation, and dry mouth. He denied any other
substance abuse.
On physical examination, his blood pressure was 112/
80 mmHg, heart rate was 108 beats/min, and temperature
was 36.5°C. The neurologic examination was unremarkable.
Laboratory tests revealed a white blood cell count of 4.38 ×
Citalopram-induced serotonin syndrome
327Kaohsiung J Med Sci July 2005 • Vol 21 • No 7
109/L, hemoglobin of 9.49 mmol/L, serum creatinine of
87.5 µmol/L, glutamic-pyruvic transaminase (GPT) of
19 U/L, and thyroid-stimulating hormone of 1.1 mU/L.
Initial therapy consisted of citalopram discontinuation,
sedation, and stool-softening agents. Two days later, the
patient showed gradual improvement. Another week later,
he was considered adequately recovered for psychiatric
evaluation in our clinic.
DISCUSSION
Our patient met the diagnostic criteria for serotonin syn-
drome according to Sternbach’s description [3], which has
been widely used [4]. He exhibited three of the symptoms
commonly associated with serotonin syndrome: agitation,
diaphoresis, and tremor after increased ingestion of a
serotonergic agent. Alternative diagnoses were ruled out
either by history or by laboratory examination.
Differential diagnosis of serotonin syndrome includes
neuroleptic malignant syndrome (NMS), dystonic reaction,
hyperthyroidism, tetanus, malignant hyperthermia, and
other disorders that produce muscle rigidity, and includes
toxicities of certain drugs such as cocaine, monoamine
oxidase inhibitors, amphetamines, lithium, and other drugs
[7]. Patients with serotonin syndrome are frequently mis-
diagnosed with NMS [8]. This is especially true in patients
taking both neuroleptic and serotonergic agents. NMS is
often confused with serotonin syndrome because mental
status changes, autonomic dysfunction, and neuromuscular
abnormalities characterize both disorders. One feature
distinguishing NMS from serotonin syndrome is the lead-
pipe rigidity associated with the former disorder compared
with the clonus and hyperreflexia seen with serotonin
syndrome. In addition, both the onset and resolution of
symptoms are faster in serotonin syndrome [7]. In our
patient, the lack of altered consciousness, severe autonomic
changes, muscle rigidity, and elevated GPT levels made the
diagnosis of NMS less likely [8]. In addition, there was no
evidence of the other differential diagnoses described above.
Citalopram is a selective serotonin reuptake inhibitor
(SSRI) antidepressant that produces a net increase in 5-HT1-
mediated transmission. Flupentixol is a phenothiazine anti-
psychotic agent, and melitracen is a tricyclic antidepressant.
Coadministration of citalopram, flupentixol, and melitracen
has not been reported to result in serotonin syndrome. In
our patient, no evidence of serotonin syndrome was noted
during drug combination therapy for more than 3 months.
However, doubling the dose of citalopram resulted in the
onset of agitation, diaphoresis, and tremor after 2 days.
Management of serotonin syndrome includes discontin-
uation of the offending serotonergic agent, supportive
therapy and, possibly, the use of serotonin antagonists
[9]. Our patient improved gradually within 2 days after
citalopram was discontinued. His condition improved
completely after another week.
Although citalopram is a relatively safe antidepressant,
serotonin syndrome needs to be considered when pre-
scribing this agent alone or in combination with other
drugs. With the increased use of SSRIs in the management
of psychiatric disorders, the importance of recognizing this
syndrome cannot be overemphasized.
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